4755:TSERakuten Group, Inc. Analysis
Data as of 2026-06-21 - not real-time
NT$145.50
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
San Fu Chemical trades at TWD 145.5, just below its 20‑day (146.3) and 50‑day (146.9) SMAs, indicating a modest pull‑back in a neutral trend. The RSI of 51.4 and a bullish MACD histogram (+0.18) suggest limited upside momentum, while decreasing volume raises concerns about the strength of any rally. Volatility is high at 46% over the past 30 days and beta is near zero, implying the stock moves independently of the broader market. Fundamentals are mixed: trailing PE is elevated at 39×, but forward PE drops to 15×, hinting that earnings are expected to improve. Revenue is contracting (‑2 %) and ROE is modest (6.3 %), yet margins remain decent (gross 21.7 %). The dividend yield of 2.54 % is attractive but the payout ratio is 94.9 %, questioning sustainability. Debt‑to‑equity sits at 30 % with a modest cash buffer, and free cash flow is positive but limited. A DCF‑derived fair value of TWD 25.5 suggests a theoretical upside of roughly 34 % versus the current price, though this figure appears anomalously low. Overall, the stock sits at a crossroads between modest valuation improvement and lingering operational headwinds.
Given the high volatility, neutral technical stance, and a dividend that may be at risk, the near‑term outlook leans toward caution. Medium‑term prospects improve if earnings guidance materializes, but the lack of clear growth and potential regulatory pressures keep the outlook restrained. Over the long horizon, the discrepancy between market price and DCF valuation, combined with a reasonable dividend yield, could make the stock an attractive value play for patient investors.
Given the high volatility, neutral technical stance, and a dividend that may be at risk, the near‑term outlook leans toward caution. Medium‑term prospects improve if earnings guidance materializes, but the lack of clear growth and potential regulatory pressures keep the outlook restrained. Over the long horizon, the discrepancy between market price and DCF valuation, combined with a reasonable dividend yield, could make the stock an attractive value play for patient investors.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Bullish MACD histogram indicating slight upside
- Price just above key support at TWD 130
- Decreasing volume and high short‑term volatility
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Forward PE of 15× suggests earnings improvement
- Revenue contraction and modest ROE temper optimism
- High dividend payout ratio may pressure cash flow
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- DCF implied upside of ~34 % versus current price
- Attractive dividend yield if payout can be moderated
- Low market beta offering defensive characteristics in a volatile environment
Key Metrics & Analysis
Financial Health
Revenue Growth-2.00%
Profit Margin7.55%
P/E Ratio39.3
ROE6.30%
ROA3.40%
Debt/Equity30.33
P/B Ratio2.6
Op. Cash FlowNT$996.4M
Free Cash FlowNT$244.8M
Technical Analysis
TrendNeutral
RSI51.4
SupportNT$130.00
ResistanceNT$165.00
MA 20NT$146.30
MA 50NT$146.87
MA 200NT$127.86
MACDBullish
VolumeDecreasing
Fear & Greed Index91.46
Valuation
Fair ValueNT$25.53
Target PriceNT$195.67
Upside/Downside34.48%
GradeFair
TypeValue
Dividend Yield2.54%
Risk Assessment
Beta-0.08
Volatility46.43%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.